Skip to content

The most accurate way to predict disease risk

The complex biology underpinning chronic diseases has made them difficult to diagnose and treat effectively, leaving millions of patients with unmet needs and making healthcare unaffordable.

Mechanostics are biomarker-driven precision medicine tests for chronic diseases that accurately identify disease risk, underlying causes, and the most effective treatments for individual patients. All consistent with a patient’s specific risk factors and mechanisms.

Mechanostics enable:
Determination of the mechanistic cause of a person's disease
Lifetime prediction and earliest detection of disease
Rapid and accurate differential triage
Personalized treatment strategies and therapy optimization

PrecisionLife - predicting disease risk-min-1
Reduce to clinical practice-min

Low-cost, scalable, rapid & non-invasive

Our mechanostic tests outperform polygenic and metabolomic diagnostics in complex conditions, are rapid, non-invasive and cost-effective.

The genotypic tests are compatible with widely available genotyping platforms used in CLIA/CAP labs around the world, accelerating their adoption and reducing the need for regulatory approval in global markets.

Predict and prevent chronic diseases that account for over 80% of all healthcare costs

Mechanostic tests have the potential to transform detection and treatment of complex diseases that affect over 5 billion lives.

Identifying a patient’s specific risk factors and disease mechanisms guides the development of personalized care pathways. These can include tailored monitoring, lifestyle changes and protective prophylactic therapies that can delay onset and prevent progression of major chronic diseases.

This is precision medicine, for everyone.

Mechanism-Based Precision Medicine

Enabling accurate risk scoring, differential triage, treatment optimization & more

Disease Risk Prediction
Patient Triage
Treatment Optimization
Clinical Trial Recruitment
Early Intervention & Prevention

Disease Risk Prediction

Identifying at-risk patients before symptoms emerge

Mechanostics enable proactive healthcare by detecting subtle, highly predictive genotypic signatures long before clinical symptoms arise. Using combinatorial analytics, our tests identify individuals at elevated risk based on the specific biological mechanisms that drive disease.

These non-invasive tests use low-cost buccal swabs to collect DNA from the lining of the patient's cheek, and are compatible with widely available genotyping arrays - making large-scale population screening practical and cost-effective.



For diagnostics

Diagnostics providers can offer next-generation risk prediction tools that add clinical value and create new revenue streams through longitudinal patient engagement.

For healthcare

Healthcare providers benefit from earlier interventions, reduced late-stage diagnoses, and the ability to shift from reactive treatment to preventative care – improving outcomes while lowering long-term costs.

Differential Triage & Accelerated Diagnosis

Pinpointing disease mechanisms for faster, more accurate referrals

Many chronic conditions have overlapping symptoms that can often result in delayed referrals and incorrect diagnoses.

Mechanostics identify the underlying biological drivers of disease in each patient, provide clear, actionable insights to accurately distinguishing between conditions.

This enables differential triage across chronic diseases to effectively manage non-specific referrals, so that patients can be allocated to the right specialty for the right procedures – preventing backlogs, reducing the need for specialist referrals and expensive confirmatory testing, and avoiding ineffective treatments.



For diagnostics 

Diagnostics providers gain high-value tools that enhance clinical accuracy, integrate seamlessly with existing genotyping platforms, and improve operational efficiency.

For healthcare

Healthcare systems benefit from reduced diagnostic delays, fewer unnecessary investigations, and faster triage to the right care pathways - optimizing resource allocation to relieve pressure on specialist services and improve patient outcomes.

Treatment Optimization

Targeting treatments to the biology that matters

Mechanostics enable targeted therapeutic decision-making by identifying the specific disease mechanisms active in each patient – stratifying patients by mechanism, and showing their most likely effective therapy.

These insights determine which patients are most likely to benefit from a given treatment – or avoid adverse reactions.

This approach enables clinicians to prioritize the treatments that align with the patient’s underlying disease biology. For example, mechanostics tests can identify chronic kidney disease patients who are most likely to benefit from Kerendia and predict complications in type-II diabetes patients to inform early therapeutic intervention and accelerate patient benefit.



For biopharma & diagnostics

Biopharmaceutical and diagnostics companies can deploy our mechanostic tests as high-value companion diagnostics that support personalized treatment strategies and improve therapy ROI.

For healthcare

Healthcare providers benefit from reduced trial-and-error prescribing, lower drug costs, and better therapeutic outcomes.

Clinical Trial Recruitment

Smarter recruitment for faster, more effective trials

Mechanostics transform trial recruitment by identifying patients with the specific genotypic and mechanistic profiles targeted by investigational therapies - improving signal detection and trial efficiency from the outset.

Our low-cost, non-invasive tests use saliva or buccal swabs and run on standard genotyping arrays compatible with CLIA/CAP-accredited labs worldwide. This makes mechanostic screening highly scalable, enabling rapid pre-screening of large patient populations across diverse sites and geographies.



For clinical trial design & enrichment

Biotech and pharma partners can run smaller, faster, and more successful trials by enrolling patients most likely to respond. Mechanistics reduce heterogeneity, improve inclusion criteria, and support enriched trial design strategies.

By combining precision recruitment with global scalability, mechanostics lower drug development risk, accelerate timelines, and increase the probability of success – helping to bring precision therapies to market faster.

Early Intervention & Prevention

Delaying and preventing disease with clinically actionable insights

Mechanostics detect an individual's lifetime risk of developing specific chronic diseases by identifying the genotypic signatures and biological mechanisms that drive disease onset.

This empowers clinicians to implement tailored early interventions - from lifestyle modifications and active monitoring to prophylactic therapies - to delay or even prevent disease progression.

PrecisionLife is uniquely positioned to go further, identifying actively protective biology that informs the development of next-generation prophylactic drugs and mRNA vaccines targeting major chronic conditions.



For diagnostics 

Diagnostics providers can expand the value of routine testing by offering predictive tools that support prevention-focused care models and public health strategies.

For healthcare

Healthcare systems benefit from a measurable reduction in future disease burden, enabling more sustainable care delivery and longer, healthier lives for patients.

Major benefits for patients, payors & providers

How mechanostics compare with traditional diagnostics

Mechanostics Diagnostics
Test Genotype Metabolomic/genetic
Sample type Buccal swab (non-invasive) Various (non-invasive – surgery)
Cost per test $ $ – $$$
Administration Self-test / Point of care Point of care / Surgical
Readout Disease risk and protective effects. Mechanisms underpinning disease. Active disease status. [Surrogate] of disease progression.
Patient insights Most likely effective treatment. Expected symptoms / clinical presentation. Likely disease trajectory (pre-symptomatic). [Surrogate] marker, may be linked to clinical endpoint. [Stage of disease, progression rate].
Applications Differential triage between similar conditions. Therapy selection by disease + mechanism. Clinical trial design & recruitment biomarkers. Early (pre-symptomatic) detection of disease risk for personal preventative health. Confirmation of disease after presentation of clinical symptoms. Early pre-symptom screening. Measurement of residual disease. [Therapy selection by disease].

From sample to solution

A simple test


Non-invasive sample taken at home or in a primary care setting, tested against an Axiom genotyping array 

Rapid results


Results delivered by our clinical decision support platform, translating disease mechanisms into actionable insights

Predicting risk


Pre-symptomatic risk detection allowing for proactive monitoring, lifestyle changes, or therapeutic interventions

Detecting cause


Identifying the underlying biology driving disease, enabling personalized care based on each patient’s specific mechanisms

"This unrivaled understanding of the mechanistic causes of disease enables us to better determine disease risk in our patients and specify which therapies are most likely to be effective in treating them."

Amy Rochlin
Chief Executive Officer
Complex Disorders Alliance

Let's talk

Patients are counting on us

We're always looking for new partners to achieve better health for patients, faster.

Contact us to request more information or discuss a collaboration.